Literature DB >> 23980070

Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat.

Md Abdul Hye Khan1, Jan Neckár, Vijay Manthati, Ramu Errabelli, Tengis S Pavlov, Alexander Staruschenko, John R Falck, John D Imig.   

Abstract

Salt-sensitive hypertension leads to kidney injury. The Dahl salt-sensitive hypertensive rat (Dahl SS) is a model of salt-sensitive hypertension and progressive kidney injury. The current set of experimental studies evaluated the kidney protective potential of a novel epoxyeicosatrienoic acid analog (EET-B) in Dahl SS hypertension. Dahl SS rats receiving high-salt diet were treated with EET-B (10 mg/kg per day) or vehicle in drinking water for 14 days. Urine, plasma, and tissue samples were collected at the end of the treatment protocol to assess kidney injury, oxidative stress, inflammation, and endoplasmic reticulum stress. EET-B treatment in Dahl SS rats markedly reduced urinary albumin and nephrin excretion by 60% to 75% along with 30% to 60% reductions in glomerular injury, intratubular cast formation, and kidney fibrosis without affecting blood pressure. In Dahl SS rats, EET-B treatment further caused marked reduction in oxidative stress with 25% to 30% decrease in kidney malondialdehyde content along with 42% increase of nitrate/nitrite and a 40% reduction of 8-isoprostane. EET-B treatment reduced urinary monocyte chemoattractant protein-1 by 50% along with a 40% reduction in macrophage infiltration in the kidney. Treatment with EET-B markedly reduced renal endoplasmic reticulum stress in Dahl SS rats with reduction in the kidney mRNA expressions and immunoreactivity of glucose regulatory protein 78 and C/EBP homologous protein. In summary, these experimental findings reveal that EET-B provides kidney protection in Dahl SS rats by reducing oxidative stress, inflammation, and endoplasmic reticulum stress, and this protection was independent of reducing blood pressure.

Entities:  

Keywords:  arachidonate epoxygenase; glomerular necrosis; hypertension; inflammation; oxidative stress

Mesh:

Substances:

Year:  2013        PMID: 23980070      PMCID: PMC3872985          DOI: 10.1161/HYPERTENSIONAHA.113.01949

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  48 in total

1.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

Review 2.  The role of the kidney in regulating arterial blood pressure.

Authors:  Hani M Wadei; Stephen C Textor
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

3.  Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension.

Authors:  Niu Tian; Kristina D Thrasher; Paul D Gundy; Michael D Hughson; R Davis Manning
Journal:  Hypertension       Date:  2005-04-18       Impact factor: 10.190

Review 4.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

5.  Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.

Authors:  Liu Liu; Chen Chen; Wei Gong; Yuanjing Li; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-16       Impact factor: 4.030

Review 6.  Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Authors:  John M Seubert; Darryl C Zeldin; Kasem Nithipatikom; Garrett J Gross
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-07-10       Impact factor: 3.072

Review 7.  Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery.

Authors:  Joseph P Marino
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

8.  Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability.

Authors:  Ming-Sheng Zhou; Ivonne Hernandez Schuman; Edgar A Jaimes; Leopoldo Raij
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-07

Review 9.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

10.  Important genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats.

Authors:  Marlene F Shehata
Journal:  Cardiovasc Diabetol       Date:  2008-06-21       Impact factor: 9.951

View more
  37 in total

1.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

Review 2.  Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.

Authors:  Fan Fan; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2017-07-12       Impact factor: 10.121

Review 3.  Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.

Authors:  John D Imig; Md Abdul Hye Khan
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

4.  Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.

Authors:  Michael A Wells; Kimberly C Vendrov; Matthew L Edin; Brian C Ferslew; Weibin Zha; Bobbie K H Nguyen; Rachel J Church; Fred B Lih; Laura M DeGraff; Kim L R Brouwer; A Sidney Barritt; Darryl C Zeldin; Craig R Lee
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-07-09       Impact factor: 3.072

Review 5.  Epoxyeicosatrienoic acids, hypertension, and kidney injury.

Authors:  John D Imig
Journal:  Hypertension       Date:  2015-01-12       Impact factor: 10.190

Review 6.  Epoxyeicosanoids in hypertension.

Authors:  J D Imig
Journal:  Physiol Res       Date:  2019-09-02       Impact factor: 1.881

Review 7.  Involvement of ENaC in the development of salt-sensitive hypertension.

Authors:  Tengis S Pavlov; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-21

Review 8.  Inflammatory macrophages in the kidney contribute to salt-sensitive hypertension.

Authors:  Daniel J Fehrenbach; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

Review 9.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

Review 10.  Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.

Authors:  J D Imig
Journal:  Adv Pharmacol       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.